Attention-deficit / hyperactivity disorder (ADHD) is a common childhood disorder that can persist into adulthood, although diagnosis and treatment initiation can occur at any age. Diagnosis and drug treatment among adults has historically lagged behind that of pediatric patients, but growing awareness of ADHD as an adult disorder—influenced in part by updated diagnostic criteria—has in recent years fueled greater industry focus on adult patients. While not all psychostimulants are approved specifically for use in adult ADHD, they are central to treating these patients, capturing the majority of U.S. patient and market share; in particular, amphetamines see greater use in adults than in the pediatric population. At the same time, nonstimulants remain key therapeutic alternatives for this population. This study uses national patient-level claims data to examine prescribing patterns of psychostimulants and nonstimulants in adult patients with ADHD to explore the distinct treatment dynamics of this market.
- Which drugs are most commonly prescribed to adult ADHD patients? What are the quarterly trends in prescribing among these patients?
- How are established brands (e.g., Takeda’s Vyvanse) and newer-to-market brands (e.g., Takeda’s Mydayis) positioned in the treatment algorithm, and what is their source of business?
- What percentage of adult ADHD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage progress to later lines of therapy within one year of diagnosis?
- What percentage of adult ADHD patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates?
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Geographies: United States
Real-world data: Longitudinal patient-level claims data analysis
Key drugs covered: Atomoxetine, guanfacine ER, methylphenidate CR, mixed amphetamine salts ER, Mydayis, Vyvanse
Key analysis provided:
- Brand / therapy usage across longitudinal patient sample
- Newly diagnosed patient analysis
- Treatment initiation and progression
- Line of therapy analysis
- Combination therapy analysis
- Source of business for recently treated patients
- Persistency and compliance analysis
- Product-level patient flowcharts
- Attention-Deficit-Hyperactivity Disorder - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis - Adult (US)
- Treatment Algorithms CDA: Adult Attention-Deficit/Hyperactivity Disorder US Mar 2020
Author(s): Audreza Das, P.G. Dip.
Audreza Das is a Senior Analyst in the CNS/Ophthalmology team at Decision Resources Group
She has authored content across indications, including neuropathic pain, age-related macular degeneration, treatment-related depression, painful diabetic neuropathy, and migraine. Ms. Das has previously worked at Novo Nordisk, as a Market Analyst for European markets. Previous experience at a SME, included developing disease competitive landscapes, covering global conferences etc. Ms. Das received her B.E. degree in Biotechnology from Birla Institute of Technology, a deemed university and her P.G. Diploma in Cancer Immunology & Biotechnology from University of Nottingham.